Provided by Tiger Trade Technology Pte. Ltd.

Corbus Pharmaceuticals

7.28
+0.02000.28%
Volume:603.94K
Turnover:4.35M
Market Cap:140.80M
PE:-1.20
High:7.38
Open:7.27
Low:7.03
Close:7.26
52wk High:20.56
52wk Low:6.33
Shares:19.34M
Float Shares:17.42M
Volume Ratio:0.34
T/O Rate:3.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0889
EPS(LYR):-5.9000
ROE:-95.58%
ROA:-53.00%
PB:1.38
PE(LYR):-1.23

Loading ...

RBC Capital Sticks to Their Buy Rating for Corbus Pharmaceuticals (CRBP)

TIPRANKS
·
Aug 12

Corbus Pharma CFO Sean Moran Sells 12,000 Shares for $120,971

Reuters
·
Aug 11

Corbus Pharmaceuticals Holdings Inc. Stock Falls 7.0%, Underperforms Peers

Dow Jones
·
Aug 11

Corbus Pharmaceuticals - to Offer and Sell Common Stock up to $127.50 Mln Through Jefferies - SEC Filing

THOMSON REUTERS
·
Aug 08

Corbus Pharmaceuticals - Enters Open Market Sale Agreement with Jefferies - SEC Filing

THOMSON REUTERS
·
Aug 08

Corbus Pharmaceuticals Holdings Inc. Stock Rises 4.4%, Outperforms Peers

Dow Jones
·
Aug 08

Corbus Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 07

Corbus Pharmaceuticals Holdings : Oppenheimer Cuts Target Price to $48 from $52

THOMSON REUTERS
·
Aug 07

Corbus Pharmaceuticals Holdings, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Corbus Pharmaceuticals Q2 EPS $(1.81) Misses $(1.26) Estimate

Benzinga Earnings
·
Aug 06

Corbus Q2 FY26 Net Loss Widens to $35.04 Million; Loss Per Share Increases to $1.81

Reuters
·
Aug 06

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 06

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 05

Corbus Pharma CMO Nicacio Leonardo Viana Files Initial Beneficial Ownership Statement

Reuters
·
Aug 05

Corbus reports last patient completes last visit in CANYON-1 trial

TIPRANKS
·
Aug 04

Corbus Says Phase 1b Canyon-1 Obesity Trial of CRB-913 Reaches Last Patient Last Visit

Reuters
·
Aug 04

Corbus Pharmaceuticals Announces Last Patient Last Visit in Canyon-1 Study of Crb-913 for the Treatment of Obesity

THOMSON REUTERS
·
Aug 04

Corbus Pharmaceuticals Holdings Inc Expected to Post a Loss of $1.26 a Share - Earnings Preview

Reuters
·
Jul 31

Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 30

Corbus Pharmaceuticals announces FDA clearance to initiate TEMPO-1 trial

TIPRANKS
·
Jul 28